• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AstraZeneca - Articles and news items


NICE recommends first drug for the Cancer Drugs Fund

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

Osimertinib is the first new cancer drug to be introduced into the NHS under a Cancer Drugs Fund managed access agreement…


MedImmune out-licenses inflammatory diseases medicine to Allergan

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is…

anti-infective drug pfizer

Pfizer to acquire AstraZeneca’s anti-infective business

Industry news / 24 August 2016 / Pfizer

The agreement includes the rights to the newly approved EU drug zavicefta (ceftazidime-avibactam), the marketed agents merrem/meronem (meropenem) and zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL…

Alzheimer's disease definition

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Industry news / 23 August 2016 / AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.


NICE recommends thousands to receive £2-a-day anti-clotting drug

Industry news / 15 August 2016 / National Institute for Health and Care Excellence (NICE)

A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke…

broken pill cancer

Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug

Industry news / 9 August 2016 / AstraZeneca

The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously…


Initiation of HTL1071 trial triggers $10m payment to Heptares

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares…

leo pharma

AstraZeneca licenses skin disease drugs to LEO Pharma

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.


AstraZeneca’s new antibiotic Zavicefta approved in the EU

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Zavicefta for the treatment of patients with serious Gram-negative bacterial infections…


Expanded Phase II trial of savolitinib in NSCLC starts

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Savolitinib is a potential global first-in-class inhibitor of c-Met, an enzyme which has been shown to function abnormally in many types of solid tumours…


AGI acquires rights to AstraZeneca’s anaesthetics portfolio outside US

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

AGI is to acquire the rights, outside the US, to AstraZeneca’s portfolio of anaesthetics for an upfront consideration of $520 million…


AstraZeneca licenses gout drug Zurampic to Grünenthal

Industry news / 2 June 2016 / Victoria White, Digital Content Producer

Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +